Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ATNMNASDAQ:EGRXOTCMKTS:NEVPFOTC:ZOMDF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATNMActinium Pharmaceuticals$1.44+0.7%$1.56$1.03▼$8.64$44.92M-0.32523,151 shs118,732 shsEGRXEagle Pharmaceuticals$3.00+3.6%$2.18$1.50▼$3.00$38.96M0.838,193 shs620 shsNEVPFAbliva AB (publ)$0.03$0.03$0.01▼$0.04$11.28M-1.184,445 shsN/AZOMDFZomedica$0.04-0.8%$0.05$0.02▼$0.17$38.61M1.564.73 million shs539,355 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATNMActinium Pharmaceuticals+5.93%-13.33%-11.73%+2.88%-80.68%EGRXEagle Pharmaceuticals+22.67%+7.22%+44.75%+93.00%-44.65%NEVPFAbliva AB (publ)0.00%0.00%0.00%0.00%+180.00%ZOMDFZomedica+1.02%+1.79%-14.62%-32.14%-72.85%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATNMActinium Pharmaceuticals2.3672 of 5 stars3.45.00.00.01.10.00.6EGRXEagle Pharmaceuticals2.2519 of 5 stars0.03.00.03.90.03.30.0NEVPFAbliva AB (publ)N/AN/AN/AN/AN/AN/AN/AN/AZOMDFZomedica0.3161 of 5 stars0.05.00.00.00.60.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATNMActinium Pharmaceuticals 2.75Moderate Buy$4.00177.78% UpsideEGRXEagle Pharmaceuticals 0.00N/AN/AN/ANEVPFAbliva AB (publ) 0.00N/AN/AN/AZOMDFZomedica 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NEVPF, ATNM, ZOMDF, and EGRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.005/12/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/28/2025ATNMActinium PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATNMActinium PharmaceuticalsN/AN/AN/AN/A$1.31 per shareN/AEGRXEagle Pharmaceuticals$257.55M0.15$7.50 per share0.40N/A∞NEVPFAbliva AB (publ)$10K1,128.43N/AN/A$0.02 per share1.40ZOMDFZomedicaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATNMActinium Pharmaceuticals-$48.82M-$1.47N/AN/AN/AN/A-100.85%-47.89%N/AEGRXEagle Pharmaceuticals$35.64MN/A0.00∞N/AN/AN/AN/AN/ANEVPFAbliva AB (publ)-$9.01MN/A0.00∞N/AN/A-117.92%-102.44%N/AZOMDFZomedicaN/A-$0.11N/A∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATNMActinium PharmaceuticalsN/AN/AN/AN/AN/AEGRXEagle PharmaceuticalsN/AN/AN/AN/AN/ANEVPFAbliva AB (publ)N/AN/AN/AN/AN/AZOMDFZomedicaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATNMActinium PharmaceuticalsN/A10.2510.25EGRXEagle PharmaceuticalsN/AN/AN/ANEVPFAbliva AB (publ)N/A7.997.99ZOMDFZomedicaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATNMActinium Pharmaceuticals27.50%EGRXEagle Pharmaceuticals85.36%NEVPFAbliva AB (publ)N/AZOMDFZomedica8.95%Insider OwnershipCompanyInsider OwnershipATNMActinium Pharmaceuticals6.00%EGRXEagle Pharmaceuticals28.90%NEVPFAbliva AB (publ)N/AZOMDFZomedica5.58%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATNMActinium Pharmaceuticals3031.20 million29.32 millionOptionableEGRXEagle Pharmaceuticals10012.99 million9.23 millionNo DataNEVPFAbliva AB (publ)8403.01 millionN/ANot OptionableZOMDFZomedica50979.95 millionN/AN/ANEVPF, ATNM, ZOMDF, and EGRX HeadlinesRecent News About These CompaniesZomedica Announces Issuance of Additional Patent for its TRUVIEW(R) MicroscopeJune 24, 2025 | accessnewswire.comAZomedica Corp.: Zomedica's Fourth Friday at Four Webinar Returns: Spotlight on TRUFORMA Diagnostic Platform - Revolutionizing In-Clinic DiagnosticsJune 19, 2025 | finanznachrichten.deZomedica's Fourth Friday at Four Webinar Returns: Spotlight on TRUFORMA Diagnostic Platform(R) - Revolutionizing In-Clinic DiagnosticsJune 19, 2025 | accessnewswire.comAZomedica Launches Enhanced Equine Insulin Assay for the TRUFORMA(R) Diagnostic Platform Featuring an Extended Range and Automatic Sample DilutionMay 21, 2025 | accessnewswire.comAZomedica Unveils Exclusive Fourth Friday at Four Webinar Series to Explore Cutting-Edge Veterinary InnovationsMay 19, 2025 | accessnewswire.comAZomedica Corp (ZOMDF) Q1 2025 Earnings Call Highlights: Record Revenue Amid Strategic ChallengesMay 16, 2025 | finance.yahoo.comZomedica Corp. (ZOMDF) Reports Q1 Loss, Lags Revenue EstimatesMay 15, 2025 | zacks.comZomedica Announces First Quarter 2025 Financial Results: Revenue of $6.5 Million; 68% Gross Margin, and $65 Million in Liquidity to Support GrowthMay 15, 2025 | accessnewswire.comAZomedica Launches Groundbreaking Equine Asthma Clinical Registry Featuring PulseVet(R) Shock Wave TherapyMay 13, 2025 | accessnewswire.comAZomedica to Report First Quarter 2025 Financial Results with a Business Update on Thursday, May 15, 2025 at 4:30 pm ETMay 9, 2025 | accessnewswire.comAZomedica CFO Scott Jordan Resigns, Interim Replacement NamedApril 30, 2025 | tipranks.comSponsored: Treating Animal Pain, Inflammation & Anxiety with Targeted Pulsed Electromagnetic Field TechnologyApril 14, 2025 | wfaa.comWZomedica Corp. (ZOMDF)April 12, 2025 | finance.yahoo.comZomedica Corp. (ZOMDF): Among Stocks Insiders Were Buying In Q1 2025April 2, 2025 | finance.yahoo.comZomedica Corp. (ZOMDF): Among Stocks Insiders Were Buying In Q1 2025April 1, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeNEVPF, ATNM, ZOMDF, and EGRX Company DescriptionsActinium Pharmaceuticals NYSE:ATNM$1.44 +0.01 (+0.70%) As of 03:30 PM EasternActinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.Eagle Pharmaceuticals NASDAQ:EGRX$3.00 +0.11 (+3.63%) As of 09:30 AM EasternEagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.Abliva AB (publ) OTCMKTS:NEVPF$0.03 0.00 (0.00%) As of 06/27/2025Abliva AB (publ), a clinical-stage biotech company, develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.Zomedica OTC:ZOMDF$0.04 0.00 (-0.76%) As of 12:58 PM EasternZomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
